论文部分内容阅读
Objective: The discovery of epidermal growth factor receptor(EGFR) mutations in NSCLC opened the era of individualized therapy.A number of clinical studies have shown the efficacy of EGFR-tyrosine kinase inhibitors (TKI) significantly associated with EGFR mutation status.